secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0000320017-25-000043
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive Cohort B ASCEND data: 6M PFS 60.8% (certepetide) vs 25% (placebo)
--------------------------------------------------------------------------

- Cohort B: median PFS 7.5 months (certepetide) vs 4.7 months (placebo); ORR 45.2% vs 19%.
- Median OS 10.32 months (certepetide) vs 9.23 months (placebo); safety profile attractive.
- Cohort B regimen (two doses of certepetide) showed clinically meaningful improvement over Cohort A.
- Full data from both cohorts expected later 2025; presented at ESMO GI on 2 July 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000043/0000320017-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001725000043/clbs-20250626.htm
  HTML page:      https://secwatch.observer/filing/0000320017-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer